Trans fat reg
This article was originally published in The Tan Sheet
Executive Summary
FDA rule requiring disclosure of trans fat on nutrition labeling slated for FY 2003 completion, agency says following July 10 release of Institute of Medicine report on the substance. IOM panel finds "positive linear trend between trans fatty acid intake and total and LDL cholesterol concentration, and therefore increased risk" of coronary heart disease, "thus suggesting an [upper limit] of zero." However, achieving the suggested UL "would require extraordinary changes in patterns of dietary intake," IOM acknowledges. Consequently, report proposes no UL but recommends trans fat consumption "be as low as possible while consuming a nutritionally adequate diet"...
You may also be interested in...
Trans Fat Footnote Statement On Food, Supplement Labeling Proposed By FDA
FDA is seeking comments on the proposed use of a footnote statement on food and dietary supplement products containing trans fat that would advise consumers against excessive intake of the ingredient
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.